| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atyr Pharma Inc (ATYR) has 4 insiders with recent SEC Form 4 filings, including 7 buys and 5 sells. ATYR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.50M | $1.42M | - | |
| Dir | 1.41M | $1.34M | - | |
| CFO | 412.5K | $390.3K | - | |
| Other | 412.5K | $390.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 20, 2020 | Schimmel Paul53 | Director | Sell | 8,447 | $3.64 | $30,738.63 | -1.9% | |
| May 20, 2020 | Denyes Nancy | General Counsel | Sale+OE | 322 | $3.62 | $1,165.64 | -10.5% | |
| Feb 10, 2020 | Schimmel Paul53 | Director | Buy | 254,000 | $4.25 | $1,079,500.00 | +138.4% | |
| Feb 7, 2020 | Shukla Sanjay66 | President And CEO | Sale+OE | 745 | $4.03 | $3,002.35 | -36.6% | |
| Feb 7, 2020 | Broadfoot Jill Marie61 | Chief Financial Officer | Sale+OE | 375 | $4.03 | $1,511.25 | -5.0% | |
| May 17, 2019 | Krueger Nancy | General Counsel | Sale+OE | 4,651 | $0.45 | $2,093.42 | -15.5% | |
| Dec 21, 2018 | Mendlein John50 | Director | Buy | 245,000 | $0.42 | $103,247.00 | +31.0% | |
| Nov 26, 2018 | Schimmel Paul53 | Director | Buy | 147,225 | $0.54 | $79,795.95 | +20.0% | |
| Sep 20, 2018 | Broadfoot Jill Marie61 | Chief Financial Officer | Buy | 64,000 | $0.83 | $52,854.80 | +82.1% | |
| Sep 14, 2018 | Broadfoot Jill Marie61 | Chief Financial Officer | Buy | 26,000 | $0.73 | $19,055.40 | New |